These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 27631111)

  • 1. Exploring the Inflammatory Metabolomic Profile to Predict Response to TNF-α Inhibitors in Rheumatoid Arthritis.
    Cuppen BV; Fu J; van Wietmarschen HA; Harms AC; Koval S; Marijnissen AC; Peeters JJ; Bijlsma JW; Tekstra J; van Laar JM; Hankemeier T; Lafeber FP; van der Greef J;
    PLoS One; 2016; 11(9):e0163087. PubMed ID: 27631111
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proteomics to predict the response to tumour necrosis factor-α inhibitors in rheumatoid arthritis using a supervised cluster-analysis based protein score.
    Cuppen B; Fritsch-Stork R; Eekhout I; de Jager W; Marijnissen AC; Bijlsma J; Custers M; van Laar JM; Lafeber F; Welsing P;
    Scand J Rheumatol; 2018 Jan; 47(1):12-21. PubMed ID: 28650254
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum Calprotectin Versus Acute-Phase Reactants in the Discrimination of Inflammatory Disease Activity in Rheumatoid Arthritis Patients Receiving Tumor Necrosis Factor Inhibitors.
    Inciarte-Mundo J; Victoria Hernández M; Ruiz-Esquide V; Raquel Cabrera-Villalba S; Ramirez J; Cuervo A; Pascal M; Yagüe J; Cañete JD; Sanmarti R
    Arthritis Care Res (Hoboken); 2016 Jul; 68(7):899-906. PubMed ID: 26841119
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Calprotectin strongly and independently predicts relapse in rheumatoid arthritis and polyarticular psoriatic arthritis patients treated with tumor necrosis factor inhibitors: a 1-year prospective cohort study.
    Inciarte-Mundo J; Ramirez J; Hernández MV; Ruiz-Esquide V; Cuervo A; Cabrera-Villalba SR; Pascal M; Yagüe J; Cañete JD; Sanmarti R
    Arthritis Res Ther; 2018 Dec; 20(1):275. PubMed ID: 30545393
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biomarkers identified by serum metabolomic analysis to predict biologic treatment response in rheumatoid arthritis patients.
    Takahashi S; Saegusa J; Onishi A; Morinobu A
    Rheumatology (Oxford); 2019 Dec; 58(12):2153-2161. PubMed ID: 31143951
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Calprotectin and TNF trough serum levels identify power Doppler ultrasound synovitis in rheumatoid arthritis and psoriatic arthritis patients in remission or with low disease activity.
    Inciarte-Mundo J; Ramirez J; Hernández MV; Ruiz-Esquide V; Cuervo A; Cabrera-Villalba SR; Pascal M; Yagüe J; Cañete JD; Sanmarti R
    Arthritis Res Ther; 2016 Jul; 18(1):160. PubMed ID: 27391315
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Can baseline serum microRNAs predict response to TNF-alpha inhibitors in rheumatoid arthritis?
    Cuppen BV; Rossato M; Fritsch-Stork RD; Concepcion AN; Schenk Y; Bijlsma JW; Radstake TR; Lafeber FP;
    Arthritis Res Ther; 2016 Aug; 18(1):189. PubMed ID: 27558398
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic drug monitoring of adalimumab in RA: no predictive value of adalimumab serum levels and anti-adalimumab antibodies for prediction of response to the next bDMARD.
    Ulijn E; den Broeder N; Wientjes M; van Herwaarden N; Meek I; Tweehuysen L; van der Maas A; van den Bemt BJ; den Broeder AA
    Ann Rheum Dis; 2020 Jul; 79(7):867-873. PubMed ID: 32317314
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interferon gene expression signature in rheumatoid arthritis neutrophils correlates with a good response to TNFi therapy.
    Wright HL; Thomas HB; Moots RJ; Edwards SW
    Rheumatology (Oxford); 2015 Jan; 54(1):188-93. PubMed ID: 25125592
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Integrative Clinical, Molecular, and Computational Analysis Identify Novel Biomarkers and Differential Profiles of Anti-TNF Response in Rheumatoid Arthritis.
    Luque-Tévar M; Perez-Sanchez C; Patiño-Trives AM; Barbarroja N; Arias de la Rosa I; Abalos-Aguilera MC; Marin-Sanz JA; Ruiz-Vilchez D; Ortega-Castro R; Font P; Lopez-Medina C; Romero-Gomez M; Rodriguez-Escalera C; Perez-Venegas J; Ruiz-Montesinos MD; Dominguez C; Romero-Barco C; Fernandez-Nebro A; Mena-Vazquez N; Marenco JL; Uceda-Montañez J; Toledo-Coello MD; Aguirre MA; Escudero-Contreras A; Collantes-Estevez E; Lopez-Pedrera C
    Front Immunol; 2021; 12():631662. PubMed ID: 33833756
    [No Abstract]   [Full Text] [Related]  

  • 11. Plasma metabolomic profiling in patients with rheumatoid arthritis identifies biochemical features predictive of quantitative disease activity.
    Hur B; Gupta VK; Huang H; Wright KA; Warrington KJ; Taneja V; Davis JM; Sung J
    Arthritis Res Ther; 2021 Jun; 23(1):164. PubMed ID: 34103083
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neutrophil biomarkers predict response to therapy with tumor necrosis factor inhibitors in rheumatoid arthritis.
    Wright HL; Cox T; Moots RJ; Edwards SW
    J Leukoc Biol; 2017 Mar; 101(3):785-795. PubMed ID: 27733572
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prealbumin, platelet factor 4 and S100A12 combination at baseline predicts good response to TNF alpha inhibitors in rheumatoid arthritis.
    Nguyen MVC; Baillet A; Romand X; Trocmé C; Courtier A; Marotte H; Thomas T; Soubrier M; Miossec P; Tébib J; Grange L; Toussaint B; Lequerré T; Vittecoq O; Gaudin P
    Joint Bone Spine; 2019 Mar; 86(2):195-201. PubMed ID: 29885551
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A genetic risk score composed of rheumatoid arthritis risk alleles, HLA-DRB1 haplotypes, and response to TNFi therapy - results from a Swedish cohort study.
    Jiang X; Askling J; Saevarsdottir S; Padyukov L; Alfredsson L; Viatte S; Frisell T
    Arthritis Res Ther; 2016 Dec; 18(1):288. PubMed ID: 27912794
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Variations in the metabolome in response to disease activity of rheumatoid arthritis.
    Tatar Z; Migne C; Petera M; Gaudin P; Lequerre T; Marotte H; Tebib J; Pujos Guillot E; Soubrier M
    BMC Musculoskelet Disord; 2016 Aug; 17(1):353. PubMed ID: 27549132
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of Tumor Necrosis Factor-Alpha Inhibitors in Children and Young Adults With Juvenile Idiopathic Arthritis or Rheumatoid Arthritis.
    Lee WJ; Briars L; Lee TA; Calip GS; Suda KJ; Schumock GT
    Pharmacotherapy; 2016 Dec; 36(12):1201-1209. PubMed ID: 27779782
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabolomic approach to the exploration of biomarkers associated with disease activity in rheumatoid arthritis.
    Sasaki C; Hiraishi T; Oku T; Okuma K; Suzumura K; Hashimoto M; Ito H; Aramori I; Hirayama Y
    PLoS One; 2019; 14(7):e0219400. PubMed ID: 31295280
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of serum anti-centromere protein F antibodies with clinical response to infliximab in patients with rheumatoid arthritis: A prospective study.
    Lourido L; Ruiz-Romero C; Picchi F; Diz-Rosales N; Vilaboa-Galán S; Fernández-López C; Tasende JAP; Pérez-Pampín E; Regueiro C; Mera-Varela A; Gonzalez A; Hambardzumyan K; Saevarsdottir S; Nilsson P; Blanco FJ
    Semin Arthritis Rheum; 2020 Oct; 50(5):1101-1108. PubMed ID: 32920323
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Estimation of heritability of different outcomes for genetic studies of TNFi response in patients with rheumatoid arthritis.
    Umićević Mirkov M; Janss L; Vermeulen SH; van de Laar MA; van Riel PL; Guchelaar HJ; Brunner HG; Albers CA; Coenen MJ
    Ann Rheum Dis; 2015 Dec; 74(12):2183-7. PubMed ID: 25114059
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness and survival-on-drug of certolizumab pegol in rheumatoid arthritis in clinical practice: results from the national Swedish register.
    Chatzidionysiou K; Kristensen LE; Eriksson J; Askling J; van Vollenhoven R;
    Scand J Rheumatol; 2015; 44(6):431-7. PubMed ID: 26084325
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.